Long‐term outcome after allogeneic stem‐cell transplantation with reduced‐intensity conditioning in patients with multiple myeloma
暂无分享,去创建一个
R. Bouabdallah | D. Blaise | D. Coso | C. Chabannon | A. Stoppa | C. Faucher | A. Granata | C. Lemarié | B. Calmels | R. Crocchiolo | J. El-Cheikh | S. Furst | P. Ladaique | J. Colella
[1] KyungMann Kim,et al. Contrasting treatment‐specific survival using double‐robust estimators , 2012 .
[2] S. Giralt,et al. Allogeneic hematopoietic stem cell transplantation for multiple myeloma: curative but not the standard of care , 2012, Current opinion in oncology.
[3] D. Blaise,et al. Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma. , 2012, Experimental hematology.
[4] R. Storb,et al. Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center , 2012, Bone Marrow Transplantation.
[5] R. Bouabdallah,et al. Allogeneic transplant for myeloma in the era of new drugs: have the outcomes improved? , 2012, Leukemia & lymphoma.
[6] A. Krishnan,et al. Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. , 2011, Blood.
[7] H. Goldschmidt,et al. Treatment of relapsed and refractory multiple myeloma in the era of novel agents. , 2011, Cancer treatment reviews.
[8] H. Einsele,et al. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] A. Zander,et al. Allogenic hematopoietic stem‐cell transplantation with reduced‐intensity conditioning in patients with refractory and recurrent multiple myeloma , 2010, Cancer.
[10] J. Bladé,et al. Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. , 2010, Blood.
[11] J. Bladé,et al. Novel drugs for the treatment of multiple myeloma , 2010, Haematologica.
[12] C. Hofmeister,et al. Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma , 2010, Leukemia & lymphoma.
[13] N. Kröger,et al. Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation , 2010, British journal of haematology.
[14] M. Baccarani,et al. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] N. Kröger,et al. Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. , 2009, Experimental hematology.
[16] B. Barlogie,et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100) , 2009, Leukemia.
[17] I. Yakoub-Agha,et al. Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. , 2008, Blood.
[18] J. Bladé,et al. Prognostic factors for multiple myeloma in the era of novel agents. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] H. Ljunggren,et al. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. , 2008, Blood.
[20] D. Blaise,et al. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma , 2008, Haematologica.
[21] R. Bouabdallah,et al. Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma , 2008, Bone Marrow Transplantation.
[22] G. Morgan,et al. Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma , 2007, Haematologica.
[23] R. Bataille,et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. , 2007, Blood.
[24] H. Goldschmidt,et al. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. , 2006, Blood.
[25] M. Qazilbash,et al. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma , 2006, Cancer.
[26] H. Einsele,et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. , 2005, Blood.
[27] R. Storb,et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. , 2003, Blood.
[28] D. Blaise,et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. , 2003, Blood.
[29] B. Barlogie,et al. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. , 2000, Blood.
[30] G. Gahrton,et al. Graft-versus-myeloma effect , 1996, The Lancet.
[31] B. Barlogie,et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. , 1995, Blood.
[32] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[33] J. Bladé,et al. 2010 Hematopoietic stem cell transplantation for multiple myeloma beyond , 2011 .
[34] M. Dimopoulos,et al. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies , 2010, Leukemia.
[35] R. Fanin,et al. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. , 2006, Haematologica.